
jul pm et
summari rank one world largest pharmaceut compani offer wide rang
price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
jul stock trade
see sale rise
follow declin aid
acquisit advers impact
divestitur hospira infus system see
robust sale brand product
ibranc xeljanz eliqui partner
bristol-my see flat sale prevnar
juli announc reorgan
three unit innov medicin
establish medicin consum health
effect think structur
increas possibl spin
establish medicin unit consist
off-pat drug made sever
acquisit bolster pipelin
mdvn billion see sale mdvn
prostat cancer drug xtandi co-promot
astella pharma grow solidli next
billion
see ep
activ buy back share
repurchas share decemb
board author new share
share remain author
may
think share trade
ep estim gener drug
peer brand drug peer near fair
valu think share trade
discount brand peer
gener unit account sale
grow slowli lower margin
expect essenti health sale improv
anticip grow biosimilar sale
continu pursu acquisit
supplement growth februari
sold hospira infus system unit icu
medic billion
announc spin essenti
unit may explor
sale consum health unit state
receiv fair valu divis
like retain invest unit
also left open potenti spin
pursu joint ventur unit think
sale could bring
risk recommend target price
includ potenti pipelin setback
target price base
ep estim brand
peer gener peer
risk assess reflect promin posit
global pharmaceut market afford
import competit oper financi
advantag howev compani still subject
inher risk common pharmaceut compani
relat discoveri develop
regulatori clearanc success commerci
jul ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview one world largest biopharmaceut comani compani
sizeabl research develop depart help develop new medicin howev compani
growth also augment acquisit past made signific acquisit
major biopharmaceut compani warner-lambert pharmacia wyeth
recent acquisit includ hospira septemb mediv septemb
drug portfolio unmatch term breadth depth global drug market view
compani largest sell drug lyrica billion sale treatment nerv pain
epilept seizur prevnar/prevnar vaccin billion key drug includ ibranc
billion treat breast cancer enbrel billion treatment moder sever plaqu
psoriasi rheumatoid arthriti sold outsid canada lipitor billion
cholesterol-low agent largest-sel drug mani year sale fell sharpli
follow expir market exclus novemb
key drug sold includ viagra million male erectil dysfunct norvasc million
antihypertens agent sutent billion kidney cancer premarin million femal
hormon replac treatment benefix million recombin coagul therapi
certain type hemophilia larg number drug gener sale hundr
million encompass treatment wide rang diseas medic condit consum health
care product includ over-the-counter medicin dietari supplement item zoeti anim health unit
spun sharehold
adjust spend total billion billion sale
sale spend downtrend recent year part on-going cost
reduct program may pipelin consist compound total
late-stag phase registr phase clinic trial phase clinic trial
compound includ new treatment wide rang condit includ cancer aid obes
arthriti heart diseas diabet schizophrenia pain
market profil dollar valu global drug market project grow compound-annual-growth-rate compound
annual growth rate accord forecast made iqvia formerli
im key driver emerg market whose aggreg sale project advanc
compound-annual-growth-rate period growth develop market spur rise
standard live grow govern spend health care howev iqvia forecast moder
trend europ sale grow compound-annual-growth-rate period
impact major develop mid-octob acquir rival drugmak wyeth
billion cash stock think acquisit significantli expand exposur
biolog vaccin new pharmaceut market februari acquir king
pharmaceut billion king brought pfizer grow portfolio novel pain treatment
well larg anim health product busi june acquir anacor pharmaceut
billion septemb acquir mediv mdvn billion januari
spun-off anim health busi new separ trade public compani call zoeti
financi trend sale risen billion billion repres
three-year compound annual growth rate sale aid acquisit advers
impact numer prescript drug lose patent protect time period gross margin
declin partli impact patent expir sever drug
adjust ep risen repres three-year compound-annual-growth-rate
although rate sale growth rate period note ep aid
signific share buyback repurchas billion share decemb
board author new billion share repurchas program
execut vice-president busi
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
slightli under-valued
bullish sinc june technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook pharmaceut
sub-industri next month neutral
although issu high drug price remain
overhang industri believ
impact lessen believ
trump administr push
regulatori chang forc drug price
may trump administr releas
drug price blueprint american patient
first view offer littl polici
regulatori chang rein escal drug
price rather see consolid
amongst largest drug purchas
health insur pharmaci benefit manag
hospit effort increas buy
firm announc rais
price drug year
signific portion firm organ
follow june drug price
innov work group draft
execut order aim tackl high drug
price draft focus reduc regul
method increas competit lower
intellectu properti right scale back
discount given hospit serv lower
incom patient import note mani
individu serv work group
former pharmaceut execut
like cfra view put forward
separ believ top-lin pressur
patent expir mani top-sel drug
bottom anticip modest
organ sale increas low-singl digit
also see expand sale new
innov drug therapi margin
improv accru cost restructur
merger synergi
see afford act
continu neg affect industri
margin see benefit includ improv
sale demand signific expans
insur popul accord
depart human servic
insur sinc law enact
howev repeal individu mandat
compon requir
peopl health insur pay fine
includ tax cut job act
pass decemb repeal
mandat effect januari
expect fewer insur patient
despit advers effect patent
expir pressur high drug price
still think long-term prospect
remain one widest-margin
industri prospect enhanc
demograph growth elderli
account industri sale
new drug discoveri number
new molecular entiti approv rebound
approv number
approv sinc
record approv follow robust
approv
approv
 pharmaceut index
increas versu rise
 composit index year date
juli pharmaceut
declin vs rise
base index
five-year market price perform jul
note sector sub-industri inform base
past perform indic futur perform
reli upon
compani
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
sale improv anticip grow biosimilar sale strong
emerg market sale indic strateg decis regard
consum healthcar busi made /jeffrey loo cfa
said review strateg altern
consumer-health unit sell brand advil centrum
chapstick gener sale believ signific
interest numer buyer capabl pay believ
unit could fetch think would use proce pursu deal
brand pharma unit struggl slow growth lack
blockbust howev ceo ian read indic would prudent wait
see tax reform enact would impact valuat asset
keep target forward ep
brand peer gener peer ep vs
line view sale account sale hospira infus
system fell innov health rose essenti health fell
say receiv approv next year
potenti blockbust half blockbust
approv think project overli optimist see
keep target ep
estim brand peer gener peer ep
vs estim sale fell note less
sell day innov health sale rose solid ibranc sale
xtandi xeljanz sale expect howev see
increas competit ibranc recent approv drug essenti
health sale fell biosimilar sale driven inflectra rose
see similar trend brand gener sale throughout /jeffrey loo
analyst research note compani news
et cfra keep hold opinion share inc
announc reorgan three busi innov
medicin establish medicin consum health care effect
believ innov medicin account sale think
structur increas possibl spin establish
medicin unit see solid growth innov medicin modest
growth establish medicin consist off-pat drug
activ seek buyer consum health care unit past
year receiv appropri offer separ state
postpon drug price increas effect juli follow public
critic includ comment presid trump ceo spoke
presid trump state deferr give presid opportun
work drug price blueprint price return pre-juli
level end year presid blueprint come
et cfra keep neutral outlook
sub-industri presid trump expect unveil plan
tackl high drug price today believ like focu two area
rebat pharmaci benefit manag pbm get drug firm
discount medicar get scenario believ trump push
portion rebat pbm receiv medicar discount pass
patient anticip trump propos allow medicar negoti
drug price drug firm ban law drug firm blame pbm
signific rise drug price increas rebat
demand pbm hand blame drug manufactur state need
higher rebat discount higher drug list price fda
commission gottlieb indic may examin rebat pbm receiv
potenti kickback potenti medicar negoti tabl
expect share drug firm react favor potenti downward
pressur pbm /jeffrey loo cfa
keep target ep estim
brand peer gener peer ep vs
ahead view partli lower tax rate vs year ago
howev sale growth sale growth forecast due
softer-than-expect sale arthriti drug xeljanz breast cancer drug
ibranc biosimilar competit europ enbrel along continu soft
sale essenti health unit lower gener price sale prevnar
fell sale intern sale say
compound develop could reach commerci
potenti achiev annual sale separ state
receiv fair valu sale consum health care
busi like retain invest unit howev also left
open potenti spin-off pursu joint ventur unit
rais target peer
ep estim set ep vs
ahead estim sale exclud divestitur
hospira infus system rose innov health sale rose strong
eliqui xeljanz sale essenti health sale fell gener
price pressur guid sale ep
use tax rate reiter decis
regard consum healthcar made /jeffrey loo cfa
et cfra keep hold opinion share inc
keep target forward ep
estim ep vs ahead estim
rais ep estim
sale account divestitur hospira infus rose innov
sale rose essenti fell look essenti
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut standard
 poor malaysia sdn bhd cfra malaysia certain research distribut
cfra uk limit cfra uk cfra uk cfra malaysia wholly-own
subsidiari cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
